Smith Jill D.
Known title: DirectorCIK: 0001463490
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Evolent Health Faces Critique, Wins Telephonic Interpretation Contract. Recent coverage highlights two contrasting stories for Evolent Health. A Yahoo piece lists three reasons to avoid the stock, while another reports that TransPerfect was chosen to provide enterprise‑wide telephonic interpretation services for Evolent. The company’s price is near its 52‑week low and below the average analyst target of $5.77, adding context to the mixed sentiment.
Transaction History
| CHKP | ▲ Buy | Grant | 1,120 | $0 | 9/2/2026 | View on chart |
| EVH | ▲ Buy | Grant | 41,096 | $0 | 6/4/2026 | View on chart |
| EVH | ▲ Buy | Grant | 23,137 | $0 | 1/2/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Check Point to report Q3 2026 results on Nov 2
Check Point Software will announce its third-quarter 2026 financial results on November 2, 2026. This upcoming report is the primary focus for investors as it will provide the latest data on the company's performance. The stock is currently trading within its 52-week range, with analysts setting an average price target of $145.83.
Check Point to report Q3 2026 results on Nov 2. Check Point Software will announce its third-quarter 2026 financial results on November 2, 2026. This upcoming report is the primary focus for investors as it will provide the latest data on the company's performance. The stock is currently trading within its 52-week range, with analysts setting an average price target of $145.83.